Accuracy of large language models in interpreting urological clinical guidelines: a comparative study with expert...

Large language models (LLMs) are increasingly being explored to supporting evidence-based decision-making in urology, but their accuracy in interpreting and applying clinical guidelines remains uncertain.

We aimed to evaluate the ability of LLMs to interpret and apply clinical guidelines across the full spectrum of major urological cancers.

This expert-validated study evaluated six configurations of three top LLMs (Claude, Gemini, and ChatGPT) using 25 structured questions for each of the seven major urological cancers: prostate cancer, upper tract urothelial carcinoma, muscle-invasive and non-muscle-invasive bladder cancer, renal cell carcinoma, penile cancer, and testicular cancer.

Both simple and rephrased prompts were used to assess the impact of prompt engineering on response quality. All figures and tables from the English-language EAU guidelines were systematically converted into plain, structured text and peer reviewed by multidisciplinary experts before evaluating the LLM responses. Each response was independently rated by 9-11 uro-oncology specialists using a five-point Likert scale (1: incorrect/unacceptable, 5: optimal), resulting in 10,500 evaluations.

Claude achieved the highest overall accuracy, with 45.9% of responses rated as optimal (Likert 5) and 87% as optimal/acceptable (Likert 4-5). Tumor-specific performance peaked in muscle-invasive bladder (56.7% optimal, 93% optimal/acceptable), penile (49.5%, 95%), and testicular cancer (60.9%, 94%). Gemini and ChatGPT showed lower optimal rates but acceptable performance (68%-70% optimal/acceptable). Rephrased prompts did not consistently outperform simple versions. All models showed acceptable accuracy, but the results should be interpreted cautiously due to recency bias and fast LLM tech evolution.

This study demonstrates the value of rigorous plain language adaptation and expert validation in benchmarking LLMs, supporting their potential as decision-support tools in uro-oncology.